Hypoxia Intolerance in Preterm Individuals (PreAlti)

August 12, 2024 updated by: Tadej Debevec, Jozef Stefan Institute

Mechanisms of Hypoxia (in)Tolerance in Prematurely Born Individuals

Reduced Hypoxic Ventilatory Response (HVR) and systemic O2 saturation subsequently leading to blunted aerobic capacity as well as decreased overall physical and cognitive performance are the main physiological challenges faced by prematurely born individuals in hypobaric hypoxia (i.e. during high altitude sojourn). While these phenomena have been described previously, the underlying mechanisms are currently unresolved. Given that the reduction in altitude-performance and its underlying mechanisms are not well understood, it is currently impossible to give evidence-based recommendation for altitude sojourns in this cohort. It is also of note, that even hypobaric hypoxia exposure during long-haul flights might be detrimental to well-being of pre-term born individuals.

The present project aims to comprehensively investigate physiological responses to altitude/hypoxia during rest and exercise in prematurely born, but otherwise healthy adults. Specifically, the investigators aim to elucidate the underlying mechanisms of the altered resting and exercise cardiovascular, respiratory, cerebral and hematological responses to hypoxia in prematurely born individuals. The obtained results from this cohort will be compared to the data from a control groups consisting of healthy, age and aerobic capacity-matched individuals born at full-term. While acute hypoxic effects will be the focus of the project's first phase, the researchers will test the effect of prolonged terrestrial (real) or simulated (normobaric hypoxia) altitude exposures in the second part. This phase will, in addition to the insight into the prolonged altitude acclimatization modulation in prematurely born individuals, also enable the potential differences between the effects of normobaric (simulated) and hypobaric (terrestrial) hypoxia in this cohort to be investigated.

Study Overview

Study Type

Observational

Enrollment (Actual)

36

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ljubljana, Slovenia, 1000
        • University of Ljubljana
      • Ljubljana, Slovenia, 1000
        • Jozef Stefan Institute
    • Canton Of Vaud
      • Lausanne, Canton Of Vaud, Switzerland, 1015
        • Institute of Sport Sciences of the University of Lausanne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Prematurely born adults involved in this study must fulfil the following characteristics at birth: gestational age ≤ 32 weeks and gestational weight ≤ 1500g.

Conversely, full-term adults involved in this study must fulfil the following characteristics at birth: gestational age of at least 38 weeks.

Description

Inclusion Criteria:

  • prematurely born (gestational age: ≤ 32 weeks; gestational weight ≤ 1500g)
  • full-term born
  • healthy individuals
  • male

Exclusion Criteria:

  • presence of any medical risk factors to exercise and/or exposure to altitude
  • presence of any medical condition that would make the protocol unreasonably hazardous for the patient
  • smokers
  • exposure to altitude above 1000m in the last 2 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Preterm born
Premature born but otherwise healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
48 hours experimental protocol conducted at sea level
Other Names:
  • Normoxic condition
  • Sea level
24 hours experimental protocol conducted in a normobaric hypoxic facility
Other Names:
  • Simulated altitude
72 hours experimental protocol conducted at terrestrial altitude
Other Names:
  • Terrestrial altitude
Full-term control
Full-term born healthy adults exposed to normoxic, normobaric hypoxic and hypobaric hypoxic interventions.
48 hours experimental protocol conducted at sea level
Other Names:
  • Normoxic condition
  • Sea level
24 hours experimental protocol conducted in a normobaric hypoxic facility
Other Names:
  • Simulated altitude
72 hours experimental protocol conducted at terrestrial altitude
Other Names:
  • Terrestrial altitude

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cerebrovascular reactivity to carbon dioxide (CO2)
Time Frame: 48 hours after exposure to normoxia and hypobaric hypoxia, respectively.
Subjects will breath 4 min 3% CO2 and 4 min 6% CO2 separated by 4 min of breathing ambient air. Gas exchange, blood flow in the middle cerebral artery and peripheral oxygen saturation will be continuously recorded by metabolic cart, transcranial doppler, and finger pulse oximeter, respectively.
48 hours after exposure to normoxia and hypobaric hypoxia, respectively.
Cognitive function
Time Frame: 24 hours after exposure to normoxia, hypobaric hypoxia, and normobaric hypoxia, respectively
Cognitive function will be assessed by a computerized psychometric test battery previously used by our research group. These will assess working memory and visuo-motor coordination.
24 hours after exposure to normoxia, hypobaric hypoxia, and normobaric hypoxia, respectively
Acute Mountain Sickness (AMS)
Time Frame: 8 hours (prior to sleep) and 16 hours (upon waking) after exposure to hypobaric and normobaric hypoxia
AMS will be assessed by Lake Louise scale. AMS will be diagnosed if the Lake Louise score is 3 or higher.
8 hours (prior to sleep) and 16 hours (upon waking) after exposure to hypobaric and normobaric hypoxia
Change in respiratory function
Time Frame: Immediately after exposure to hypobaric and normobaric hypoxia, relative to baseline.
Respiratory function will be assessed by spirometry.
Immediately after exposure to hypobaric and normobaric hypoxia, relative to baseline.
Lung comets
Time Frame: Every day before and immediately after each exercise bout.
Lung comets will be assessed by counting the number of B-lines present, which will be measured using Doppler ultrasound.
Every day before and immediately after each exercise bout.
Changes in the rate of muscular oxygen consumption (mV̇O2)
Time Frame: Before each exercise bouts.
Muscle oxygen consumption will be assessed using a previously validated protocol. Briefly, a Near Infra-Red Spectroscopy (NIRS) optode will be placed on the vastus lateralis muscle. Before the protocol, an ischemic calibration will be performed to normalize the NIRS signals by inflating the blood pressure cuff to 250-300 mmHg for a maximum of 5 min. Resting mV̇O2 will be assessed from the decrease in muscle oxygenation which accompanies the arterial occlusion. Four resting measurements will be performed using 10 sec of arterial occlusion. Then, each subject will perform a voluntary knee extension exercise for 15 sec. To measure the recovery of oxygen consumption after exercise, subject will have a series of arterial occlusion as follows: 5 occlusions 5sec on-5sec off, 5 occlusions 5sec on-5sec off, and 8 occlusions 10 sec on-20 sec off.
Before each exercise bouts.
Acute change in sleep quality
Time Frame: On the first night in normoxia, normobaric hypoxia and hypobaric hypoxia.
Polysomnography will be used to assess sleep quality. Measurements will include electroencephalography (EEG), electrooculography (EOG), chin and tibial surface electromyography (EMG), electrocardiography (ECG), nasal pressure (nasal pressure cannula), respiratory movements (chest and abdominal belts) as well as capillary oxygenated haemoglobin saturation measurement.
On the first night in normoxia, normobaric hypoxia and hypobaric hypoxia.
Change in sleep quality after prolonged exposure to hypobaric hypoxia
Time Frame: On the third night after exposure to terrestrial altitude.
Polysomnography will be used to assess sleep quality. Measurements will include electroencephalography (EEG), electrooculography (EOG), chin and tibial surface electromyography (EMG), electrocardiography (ECG), nasal pressure (nasal pressure cannula), respiratory movements (chest and abdominal belts) as well as capillary oxygenated haemoglobin saturation measurement.
On the third night after exposure to terrestrial altitude.
Changes in endothelial capacity to flow-mediated dilation (FMD)
Time Frame: 24 hours after exposure to normoxia and hypobaric hypoxia.
A pneumatic cuff is positioned distal to the ultrasound probe in order to avoid ischemia of the artery studied. Radial artery diameter is measured at rest, during inflation of the distal cuff to suprasystolic pressure (5 min) and for the 5 min following deflation. The subsequent decrease in local blood flow in response to ischemia causes a progressive decrease in the radial artery diameter until a plateau (L-FMC). Upon cuff deflation, the increased blood flow causes radial artery dilatation. L-FMC is calculated as the percentage decrease in arterial diameter in the last 30 s of cuff occlusion as compared with resting diameter. FMD is calculated as the maximum percentage increase in arterial diameter following cuff deflation.
24 hours after exposure to normoxia and hypobaric hypoxia.
Changes in orthostatic tolerance
Time Frame: At 6am on every trial day (upon waking).
Orthostatic tolerance will be assessed by measuring heart rate variability. This will involve an app-validated 10-min protocol, which will use a chest-band to monitor heart rate changes from 5 minutes of supine position followed by 5 minutes of standing.
At 6am on every trial day (upon waking).
Changes in oxidative stress markers in the blood
Time Frame: Blood samples will be collected at 6am (upon waking).
Oxidative stress markers concentration will be measured on collected venous blood sample.
Blood samples will be collected at 6am (upon waking).
Change in salivary cortisol concentration
Time Frame: Saliva samples will be collected at 6am (upon waking).
Cortisol concentration will be measured on collected saliva samples.
Saliva samples will be collected at 6am (upon waking).
Change in hydration status
Time Frame: Urine samples will be collected at 6am (upon waking).
Urine samples will be assessed using urine specific gravity.
Urine samples will be collected at 6am (upon waking).
Heart rate response to exercise
Time Frame: Every day before exercise, during exercise and at the instant of volitional exhaustion.
Heart rate (HR, bpm) will be continuously monitored during different exercise bouts of variety intensities (moderate and heavy intensities will be used).
Every day before exercise, during exercise and at the instant of volitional exhaustion.
Respiratory response to exercise
Time Frame: Every day before exercise, during exercise and at the instant of volitional exhaustion.
Oxygen consumption (VO2, L/min and mL/min/kg) will be continuously monitored during different exercise bouts of variety intensities (moderate and heavy intensities will be used).
Every day before exercise, during exercise and at the instant of volitional exhaustion.
Changes in muscular oxygenation during exercise
Time Frame: Every day before exercise, during exercise and at the instant of volitional exhaustion.
Muscle oxygenation/deoxygenation will be continuously recorded during each exercise bout by Near Infra-Red Spectroscopy (NIRS) placed on the vastus lateralis. NIRS measure the quantity of oxygenated and deoxygenated haemoglobin and myoglobin (microM) in the investigated areas (vastus lateralis).
Every day before exercise, during exercise and at the instant of volitional exhaustion.
Changes in cerebral oxygenation during exercise
Time Frame: Every day before exercise, during exercise and at the instant of volitional exhaustion.
Brain oxygenation/deoxygenation will be continuously recorded during each exercise bout by Near Infra-Red Spectroscopy (NIRS) placed at the frontal levels. NIRS measure the quantity of oxygenated and deoxygenated haemoglobin (microM) in the investigated areas (prefrontal cortex).
Every day before exercise, during exercise and at the instant of volitional exhaustion.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in cerebral blood flow in the internal carotid artery
Time Frame: Cerebral blood flow will be measured at 10am.
Cerebral blood flow in the internal will be assessed every morning by doppler ultrasound.
Cerebral blood flow will be measured at 10am.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 30, 2021

Primary Completion (Actual)

March 31, 2022

Study Completion (Actual)

March 31, 2022

Study Registration Dates

First Submitted

January 22, 2021

First Submitted That Met QC Criteria

February 1, 2021

First Posted (Actual)

February 5, 2021

Study Record Updates

Last Update Posted (Actual)

August 15, 2024

Last Update Submitted That Met QC Criteria

August 12, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypoxia

Clinical Trials on Normoxia

Subscribe